NCT04278859View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of a Recombinant Humanized mAb Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

April 28, 2020

Primary Completion Date

July 13, 2023

Study Completion Date

July 13, 2023

Conditions
Advanced Solid Tumor
Interventions
BIOLOGICAL

Drug: JS004, Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection Intravenous infusion

Drug: JS004, Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection Intravenous infusion

Trial Locations (1)

100021

Cancer Hospital Chinese Academy of Medical Sciences, Beijin

All Listed Sponsors
lead

Shanghai Junshi Bioscience Co., Ltd.

OTHER

NCT04278859 - Safety, Tolerability and Pharmacokinetics of a Recombinant Humanized mAb Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced Malignancies | Biotech Hunter | Biotech Hunter